{
  "input_text": "other key inclusion criteria is as follows, help find and add them to the previous trial protocol: Evidence of first-line platinum-based chemotherapy combined with a PD-1 or PD-L1 inhibitor, identified via medication administration records. Discontinuation of first-line therapy prior to initiation of second-line docetaxel-based treatment. Second-line treatment initiated within routine oncology care (outpatient infusion setting).",
  "decision_plan": {
    "mode": "trial_parser",
    "composite_term_strategy": {
      "enabled": true,
      "require_multi_term_for_composites": true,
      "default_min_components": 2
    },
    "composite_definitions": [
      {
        "name": "Outpatient oncology care",
        "min_components": 2,
        "components": [
          {
            "role": "diagnosis",
            "required_systems": [
              "ICD10CM",
              "ICD10"
            ],
            "description": "Oncology diagnosis term(s), e.g., NSCLC or malignancy."
          },
          {
            "role": "visit_type",
            "required_systems": [
              "CPT4",
              "CPT"
            ],
            "description": "Outpatient office/oncology encounter term."
          }
        ]
      }
    ]
  },
  "inclusion_concepts": [],
  "exclusion_concepts": [],
  "temporal_constraints": [],
  "outcomes": [],
  "concept_mappings": [],
  "composite_concepts": []
}